CNS Pharmaceuticals’ (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Company on track to achieve value-driving milestones before year-endHOUSTON, TX / ACCESSWIRE / October 11, 2023 / CNS Pharmaceuticals, Inc....